HBIO logo

HARVARD BIOSCIENCE INC

HBIONASDAQ
πŸ† #4398 by market capEarnings Nov 10US Equity
$8.42β–² $0.07 (+0.84%)
πŸŒ… Pre-market$8.42β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track HBIO
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.8%
7dβ–² 3.3%
14dβ–² 2.4%
30dβ–² 5.4%
ytdβ–² 26.9%
1yβ–² 90.1%
🏦Market Cap
$38M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-1.1%
Declining
πŸ“ŠGross Margin
58.2%
Healthy
πŸ’΅FCF Margin
7.8%
Moderate
βš–οΈP/S Ratio
0.4x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$8.32 – $8.47
52-Week Range
$3.95 – $9.40
Volume (shares)
7,983
Avg Volume (shares)
β€”
Shares Outstanding
4.5M
Next Earnings
2026-11-10

Fundamentals Snapshot

Annual Revenue
$87M
Last Q Revenue
$23M
P/E Ratio
β€”
P/S Ratio
0.4x
EPS (TTM)
$-2.32
Dividend Yield
β€”
Dilution (1yr)
+2.0%
HBIO logo

HARVARD BIOSCIENCE INC

HBIO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$87Mβ–Ό βˆ’8.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
53.0%β–Ό βˆ’8.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$629Kβ–Ό βˆ’89.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$6Mβ–Ό βˆ’408.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.4Mβ–² +2.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$36Mβ–² +$5M YoY
StockOtter Β· stockotter.space

About HARVARD BIOSCIENCE INC

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
8 analysts
Strong Buy2
Buy4
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates